摘要
目的:观察肾炎四补丸联合达格列净治疗脾肾气虚型糖尿病肾病(DKD)的疗效及安全性。方法:选取2022年1月—2023年2月盐城市中医院肾病科收治的DKD患者60例,随机数字表法分为研究组和对照组,每组30例。两组均行常规治疗,对照组在常规治疗基础上给予达格列净治疗,研究组在对照组基础上给予肾炎四补丸治疗。比较两组患者临床疗效、中医证候积分、肾功能[尿素氮(BUN)、血肌酐(Scr)、肾小球滤过率(eGFR)]、尿多项蛋白检测[尿白蛋白/肌酐比值(ACR)、尿β2微球蛋白(尿β2-MG)、尿α1微球蛋白(尿α1-MG)]、血糖[餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、空腹血糖(FPG)]和不良反应的发生率。结果:研究组临床疗效高于对照组(P<0.05)。治疗后,两组患者中医证候积分、Scr、BUN、UTP、ACR、尿β2-MG、尿α1-MG均降低(P<0.05),且研究组低于对照组(P<0.05);eGFR均升高(P<0.05),且研究组高于对照组(P<0.05)。治疗前后两组患者FPG、2 h PG、HbA1c水平显著降低(P<0.05),但两组间对比无显著差异(P>0.05)。两组患者不良反应发生率比较无显著差异(P>0.05)。结论:肾炎四补丸联合达格列净治疗DKD患者疗效显著,可有效缓解其临床症状,控制血糖,延缓肾功能的进展,减轻尿蛋白,且安全性较高。
Objective:To observe the efficacy and safety of Shenyan Sibu pill combined with dapagliflozin in the treatment of diabetic kidney disease(DKD)of spleen kidney qi deficiency type.Methods:Sixty DKD patients admitted to Nephrology Department of Yancheng Hospital of Traditional Chinese Medicine from January 2022 to February 2023 were selected and divided into study group and control group by random number table method,with 30 cases in each group.Both groups received routine treatment.However,the control group received dapagliflozin treatment in addition to the routine treatment,and the study group received Shenyan Sibu pill treatment plus the routine treatment and dapagliflozin treatment.The clinical efficacy,TCM syndrome score,renal function[Blood urea nitrogen(BUN),serum creatinine(Scr),glomerular filtration rate(eGFR)],urine multiple proteins[urinary microalbumin/creatinine ratio(ACR),urine 2 microglobulin(urineβ2-MG),urineα1 microglobulin(urineα1-MG)],blood glucose[postprandial blood glucose(2hPG),Glycated hemoglobin(HbA1c),Fasting blood sugar(FPG)]levels and adverse reaction rate were compared.Results:The clinical efficacy of the study group was higher than that of the control group(P<0.05).After treatment,the TCM syndrome scores,Scr,BUN,UTP,ACR,urineβ2-MG,and urineα1-MG of both groups decreased(P<0.05),and were lower in the study group than in the control group(P<0.05);and eGFR increased(P<0.05),and was higher in the study group than in the control group(P<0.05).The levels of FPG,2 h PG and HbA1c significantly decreased in the two groups(P<0.05),but there was no significant difference between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion:Shenyan Sibu pill combined with dapagliflozin has a significant effect on DKD patients,which can effectively alleviate their clinical symptoms,control blood sugar,delay the progress of renal function damage,and reduce urinary protein,and has a high safety.
作者
徐晶
吴中繁
时洪娟
张侃
XU Jing;WU Zhongfan;SHI Hongjuan;ZHANG Kan(Department of Nephrology,Yancheng Hospital of Traditional Chinese Medicine,Yancheng 224000,China)
出处
《中医药学报》
CAS
2024年第5期85-89,共5页
Acta Chinese Medicine and Pharmacology
基金
江苏省中医药科技项目(YB202073)
盐城市科技计划项目(Yk2021042)。
关键词
肾炎四补丸
达格列净
糖尿病肾病
临床疗效
安全性
Shenyan Sibu pill
Dapagliflozin
Diabetic kidney disease
Clinical efficacy
Security
